health department

Transparency, honesty, and collaboration are necessary to do science, including biomedical and clinical science right.  In the US, the National Institutes of Health (NIH) have always had a good reputation for transparency, honesty and collaboration, although they have had some revolving door and conflict of interest issues of late (look here, here, here here, and here). However, an April 3

Dr Scott Gottlieb, the first commissioner of the US Food and Drug Administration (FDA) appointed by President Trump, has announced his plans to depart.  At the time of his nomination, Dr Gottlieb's many conflicts of interest were well known (see this NY Times article, for example), as were his exceedingly friendly views of the pharmaceutical/ biotechnology industry (see this long ago post, for

While we were distracted by the daily onslaught of news, it appears that the revolving door continues to spin. This month there has been a flurry of transitions from big health care and health care related corporations to the federal government.  So it appeared to be time for another revolving door update. We start with a transition from a few months ago that we had not previously